Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

A collection of 60 cell lines derived from human tumors (NCI-60) has been widely explored as a tool for anticancer drug discovery. Here, we profiled the cell surface of the NCI-60 by high-throughput screening of a phage-displayed random peptide library and classified the cell lines according to the binding selectivity of 26,031 recovered tripeptide motifs. By analyzing selected cell-homing peptide motifs and their NCI-60 recognition patterns, we established that some of these motifs (a) are similar to domains of human proteins known as ligands for tumor cell receptors and (b) segregate among the NCI-60 in a pattern correlating with expression profiles of the corresponding receptors. We biochemically validated some of the motifs as mimic peptides of native ligands for the epidermal growth factor receptor. Our results indicate that ligand-directed profiling of tumor cell lines can select functional peptides from combinatorial libraries based on the expression of tumor cell surface molecules, which in turn could be exploited as "druggable" receptors in specific types of cancer.

[1]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[2]  R Pasqualini,et al.  Molecular addresses in blood vessels as targets for therapy. , 2001, Current opinion in chemical biology.

[3]  P. Troncoso,et al.  Combinatorial Screenings in Patients , 2004, Cancer Research.

[4]  Anders Wallqvist,et al.  Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data , 2003, Bioinform..

[5]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[6]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[7]  J. Brown,et al.  NCI's anticancer drug screening program may not be selecting for clinically active compounds. , 1997, Oncology research.

[8]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[9]  E. Sausville,et al.  Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. , 2002, Journal of medicinal chemistry.

[10]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[11]  J N Weinstein,et al.  A protein expression database for the molecular pharmacology of cancer , 1997, Electrophoresis.

[12]  Anders Wallqvist,et al.  Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. , 2002, Molecular cancer therapeutics.

[13]  S. Holbeck,et al.  Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.

[14]  W. Arap,et al.  Teratogenicity induced by targeting a placental immunoglobulin transporter , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Wadih Arap,et al.  Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.

[16]  Wadih Arap,et al.  Reversal of obesity by targeted ablation of adipose tissue , 2004, Nature Medicine.

[17]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[18]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[19]  D. Zaharevitz,et al.  COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition. , 2002, Journal of molecular graphics & modelling.

[20]  Carlos F. Barbas,et al.  Phage display: a Laboratory manual , 2014 .

[21]  William C Reinhold,et al.  Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Kim-Anh Do,et al.  Steps toward mapping the human vasculature by phage display , 2002, Nature Medicine.

[23]  J. Weinstein,et al.  Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.

[24]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.